MATTERHORN: Edge-to-Edge Repair vs. Surgery for Secondary Mitral Valve Regurgitation

Frequently associated with hospitalization for cardiac failure and mortality, secondary mitral valve regurgitation (MR) is the most common cause of mitral insufficiency.

Current guideline recommendation is surgery. However, some studies have shown edge-to-edge repair (TEER) is effective for patients with favorable anatomy and high surgical risk.  

The MATTTERHORN, a randomized multicenter clinical trial, included 208 patients allocated 1:1 to TEER or surgery (repair or replacement).

For study inclusion, significant mitral insufficiency was defined as effective regurgitant orifice area ≥20 mm², contracted vein >8 mm, regurgitant volume ≥30 ml, ≥50% ejection fraction and at least 2 hospitalizations for DF within prior 12 months.

Primary efficacy end point was a combination of all cause death, hospitalization for CF, reintervention, new ventricular assist device implantation, or stroke, at 12 months.

Read also: ESC 2024 | The OCCUPI Trial: Guided PCI for OCT in Complex Lesions.

Baseline characteristics were similar: mean age 70, 39% women, 26% diabetic, 83% hypertensive, 44% CAD, 3.4% CABG, 51% atrial fibrillation, 6% stroke and 35% kidney function deterioration. STS score was 2% and EuroSCORE 3%.

Most patients were in functional class III-IV. 96% presented mitral valve insufficiency grade 3+ or higher, with 22 mm² effective regurgitant area and 43% ejection fraction.

There were no differences between TEER and surgery at one year.

At 12 month followup, there were no significant differences as regards success between TEER and surgery. Efficacy end point resulted non-inferior with TEER vs surgery (16.7% vs. 22.5%; estimated mean difference, −6 perceptual points, CI 95%, −17 to 6; P<0.001 for non-inferiority). There were no differences in all-cause mortality, hospitalization for cardiac failure, reintervention, ventricular assist device implantation or stroke.

Read also: ESC 2024 | REC-CAGEREE I Trial: Drug Coated Balloon with Bailout Stenting vs. Intended DES for de Novo Lesion Treatment.

Both groups showed improved functional class, 6-minute walk test and maintained MR reduction at one year followup. 

Conclusion

In patients with cardiac failure and secondary mitral valve regurgitation, TEER resulted non-inferior vs mitral valve surgery as regards the composite of death, rehospitalization for CF, stroke, reintervention or ventricular assist device implantation at one year. 

Original Title: Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation. For the MATTERHORN Investigators.

Reference: Stephan Baldus, et al. NEJM 2024 DOI: 10.1056/NEJMoa2408739.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...